PL371963A1 - Farmaceutyczna kompozycja zawierająca N-[(1-n-butylo-4-piperydynylo)metylo]-3,4-dihydro-2H-[1,3]oksazyno[3,2-a]indolo-10-karboksamid albo jego sól i sposób jej wytwarzania obejmujący granulowanie na sucho - Google Patents

Farmaceutyczna kompozycja zawierająca N-[(1-n-butylo-4-piperydynylo)metylo]-3,4-dihydro-2H-[1,3]oksazyno[3,2-a]indolo-10-karboksamid albo jego sól i sposób jej wytwarzania obejmujący granulowanie na sucho

Info

Publication number
PL371963A1
PL371963A1 PL03371963A PL37196303A PL371963A1 PL 371963 A1 PL371963 A1 PL 371963A1 PL 03371963 A PL03371963 A PL 03371963A PL 37196303 A PL37196303 A PL 37196303A PL 371963 A1 PL371963 A1 PL 371963A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
salt
dry granulation
granules
weight
Prior art date
Application number
PL03371963A
Other languages
English (en)
Other versions
PL206544B1 (pl
Inventor
Philip Christopher Buxton
Sharon Elizabeth Groves
Seona Thomson
Schie Dirk Marinus Johannes Van
Kenneth Trevor Yeates
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL371963A1 publication Critical patent/PL371963A1/pl
Publication of PL206544B1 publication Critical patent/PL206544B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL371963A 2002-02-14 2003-01-22 Sposób wytwarzania farmaceutycznej kompozycji zawierającej N-[(1-n-butylo-4-piperydynylo)metylo]-3,4-dihydro-2H-[1,3]oksazyno [3,2-a]indolo-10-karboksamid, albo jego farmaceutycznie dopuszczalną sól PL206544B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition

Publications (2)

Publication Number Publication Date
PL371963A1 true PL371963A1 (pl) 2005-07-11
PL206544B1 PL206544B1 (pl) 2010-08-31

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371963A PL206544B1 (pl) 2002-02-14 2003-01-22 Sposób wytwarzania farmaceutycznej kompozycji zawierającej N-[(1-n-butylo-4-piperydynylo)metylo]-3,4-dihydro-2H-[1,3]oksazyno [3,2-a]indolo-10-karboksamid, albo jego farmaceutycznie dopuszczalną sól

Country Status (21)

Country Link
US (1) US20050075335A1 (pl)
EP (1) EP1476136B1 (pl)
JP (1) JP2005523276A (pl)
KR (1) KR100967782B1 (pl)
AT (1) ATE329581T1 (pl)
AU (1) AU2003202058B2 (pl)
BR (1) BR0307666A (pl)
CA (1) CA2475659A1 (pl)
CO (1) CO5611095A2 (pl)
CY (1) CY1106148T1 (pl)
DE (1) DE60306120T2 (pl)
DK (1) DK1476136T3 (pl)
ES (1) ES2263949T3 (pl)
IS (1) IS2393B (pl)
MX (1) MXPA04007857A (pl)
NO (1) NO20043834L (pl)
NZ (1) NZ534333A (pl)
PL (1) PL206544B1 (pl)
PT (1) PT1476136E (pl)
RU (1) RU2329789C2 (pl)
WO (1) WO2003068193A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AU2007248613A1 (en) * 2006-05-04 2007-11-15 Novartis Ag Heated roller compaction process for making pharmaceutical compositions
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CN101778624A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
CN101772304B (zh) * 2007-07-31 2014-07-09 卡吉尔公司 直接可压缩的右旋糖
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) * 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
EP0376331A3 (en) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
JP3911297B2 (ja) * 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
CA2418904A1 (en) * 2000-08-07 2002-02-14 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
JP2004505920A (ja) * 2000-08-08 2004-02-26 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 縮合インドール化合物を含む医薬組成物
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
WO2003068193A1 (en) 2003-08-21
MXPA04007857A (es) 2004-10-15
RU2004127450A (ru) 2005-04-10
CY1106148T1 (el) 2011-06-08
AU2003202058B2 (en) 2009-05-28
DE60306120D1 (de) 2006-07-27
IS2393B (is) 2008-08-15
RU2329789C2 (ru) 2008-07-27
EP1476136A1 (en) 2004-11-17
KR20040097996A (ko) 2004-11-18
JP2005523276A (ja) 2005-08-04
PL206544B1 (pl) 2010-08-31
CO5611095A2 (es) 2006-02-28
IS7398A (is) 2004-08-12
DK1476136T3 (da) 2006-10-09
EP1476136B1 (en) 2006-06-14
CA2475659A1 (en) 2003-08-21
DE60306120T2 (de) 2006-11-09
HK1072359A1 (en) 2005-08-26
KR100967782B1 (ko) 2010-07-05
NO20043834L (no) 2004-10-26
US20050075335A1 (en) 2005-04-07
AU2003202058A1 (en) 2003-09-04
ES2263949T3 (es) 2006-12-16
PT1476136E (pt) 2006-10-31
NZ534333A (en) 2006-05-26
BR0307666A (pt) 2005-01-11
ATE329581T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
PL371963A1 (pl) Farmaceutyczna kompozycja zawierająca N-[(1-n-butylo-4-piperydynylo)metylo]-3,4-dihydro-2H-[1,3]oksazyno[3,2-a]indolo-10-karboksamid albo jego sól i sposób jej wytwarzania obejmujący granulowanie na sucho
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
CA2487834A1 (en) Orally disintegrating tablets and process for obtaining them
YU19301A (sh) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
MXPA02003203A (es) Composiciones terapeuticas solubles en tocol.
AU1531199A (en) Pharmaceutical suspension tablet compositions
SA94150373A (ar) صياغات جديدة واستخدام صياغة في علاج و/أوالوقاية من اضطرابات معينة
CA2280310A1 (en) Nmda antagonist
SG162605A1 (en) Pharmaceutical compositions
CA2353693A1 (en) Pharmaceutical composition containing citalopram
TW200509995A (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
AU2002258002A1 (en) A process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose
TW200505504A (en) Saquinavir mesylate oral dosage form
CA2217238A1 (en) Cross-linked cellulose as a tablet excipient
CA2454449A1 (en) Synergistic filler composition of pvp-va and silicified mycrocrystalline cellulose for tablet dosage form
WO2008012474A3 (fr) Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
WO2004045580A3 (en) Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
WO2007010369B1 (en) Sustained release formulation of alprazolam
MXPA05011591A (es) Composicion farmaceutica como forma de dosificacion solida y metodo para la elaboracion de la misma.
YU54503A (sh) Farmaceutski sastav koji sadrži citalopram
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
WO2006052254A3 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20120122